Norway, April 15 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has initiated a technology evaluation agreement in the area of in vivo CAR-T cell therapy with Acuitas Therapeutics, based in Vancouver, Canada.In vivo CAR-T cell therapy is a novel therapeutic area of high R&D and deal activity in the pharmaceutical industry. Current mRNA-based approaches are promising, but the short duration of expression of only a few days may limit their efficacy and applicability. Circio has previously reported that its proprietary circVec technology can achieve up to six months expression in lymphocytes in vivo. This feature provides an extended therapeu...